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Abstract
Aim Anastomotic leak (AL) is a major complication of
rectal cancer surgery. Despite advances in surgical practice,
the rates of AL have remained static, at around 10–15%.
The aetiology of AL is multifactorial, but one of the most
crucial risk factors, which is mostly under the control of
the surgeon, is blood supply to the anastomosis. The
MRC/NIHR IntAct study will determine whether assess-
ment of anastomotic perfusion using a fluorescent dye (in-
docyanine green) and near-infrared laparoscopy can
minimize the rate of AL leak compared with conventional
white-light laparoscopy. Two mechanistic sub-studies will
explore the role of the rectal microbiome in AL and the
predictive value of CT angiography/perfusion studies.
Method IntAct is a prospective, unblinded, parallel-
group, multicentre, European, randomized controlled trial
comparing surgery with intra-operative fluorescence
angiography (IFA) against standard care (surgery with no
IFA). The primary end-point is rate of clinical AL at
90 days following surgery. Secondary end-points include
all AL (clinical and radiological), change in planned anas-
tomosis, complications and re-interventions, use of stoma,
cost-effectiveness of the intervention and quality of life.
Patients should have a diagnosis of adenocarcinoma of the
rectum suitable for potentially curative surgery by anterior
resection. Over 3 years, 880 patients from 25 European
centres will be recruited and followed up for 90 days.
Discussion IntAct will rigorously evaluate the use of
IFA in rectal cancer surgery and explore the role of the
microbiome in AL and the predictive value of preopera-
tive CT angiography/perfusion scanning.
Keywords Intra-operative fluorescence angiography, re-
section, rectal cancer, anastomotic leak, randomized
controlled trial
Background
The most feared complication of rectal cancer surgery
is anastomotic leak (AL), which is reported in 10–15%
of patients [1,2]. AL has a negative impact on patient
recovery and consumes a considerable amount of
health resources for remedial interventions. It increases
postoperative morbidity from ~20% to ~60% and mor-
tality from < 5% to ~20%, and extends in-patient stay
by an additional 7 days on average [2–4]. Patients who
survive AL suffer long-term consequences with
reduced quality of life (QoL), high rates of wound
complications, permanent stoma and increased risk of
cancer recurrence [5–8].
Several risk factors have been implicated in AL,
including technical aspects of anastomosis construc-
tion (e.g. poor blood supply, inadequate tissue
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angiography (IFA) against standard care (surgery with no IFA) to determine
the effect on anastomotic leak in patients undergoing elective laparoscopic or
robot-assisted anterior resection for rectal cancer
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approximation and tension on the anastomosis) and
patient risk factors associated with poor tissue healing
(e.g. malnutrition and immunosuppression) [9,10]. Of
all the factors that contribute to AL, probably the most
crucial and the one that the surgeon has some influence
over, is the blood supply to the anastomosis [11].
Unfortunately, assessment of anastomotic perfusion is
difficult during surgery, as demonstrated by the sur-
geon’s inability to predict AL [12].
Intra-operative fluorescence angiography (IFA) has
been introduced to evaluate anastomotic blood supply,
with promising early results. The technique involves
intravenous administration of indocyanine green (ICG),
which rapidly binds to plasma proteins and stays in the
intravascular compartment. When irradiated with near-
infrared light (NIR), ICG fluorescence can be visualized
on standard visual display units, providing an image of
tissue perfusion.
Proof of concept has been established, but evidence
is limited [13–20]. A multicentre, nonrandomized study
– Perfusion Assessment in Laparoscopic Left Anterior
Resection (PILLAR II) reported an AL rate of 1.4% in
139 patients available for analysis, which represents a
reduction of eight- to nine-fold in the documented leak
rate of 12% following anterior resection (AR) [16].
Degett et al.’s systematic review of 10 small nonran-
domized trials (n = 916) of IFA in colorectal anasoto-
mosis surgery supports the early data of PILLAR II.
The addition of IFA gave a pooled incidence of AL of
3.83% (95% CI: 2.64–5.02%) in colorectal resection
surgery [17].
Although good surgical technique and optimal
blood supply are paramount for anastomotic healing,
there is increasing evidence to support a role for the
gut microbiome [21]. Using a rat model of AL, Sho-
gan et al. [22] showed that anastomotic injury results
in a change in anastomotic tissue-associated micro-
biota, with upregulation of bacterial virulence-
associated pathways.
Neoadjuvant radiotherapy was used in the treatment
of 37% of rectal cancers in the UK in 2014/2015 [23].
Although beneficial in reducing the risk of local cancer
recurrence, preoperative radiotherapy increases the risk
of AL [10,24–26] through effects on the bowel
microvasculature and possible alteration in the rectal
microbiota [27–30]. Through the use of contrast-
enhanced CT angiography, it is possible to assess the
anatomical variation in blood supply to the bowel, while
perfusion CT can provide valuable quantitative informa-
tion regarding bowel-wall blood flow, blood volume
and vascular leakage rate [31–33]. The combination of
CT angiography and perfusion CT may have a role in
predicting AL and guiding operative decision-making.
Method
Overall trial aims
IntAct will investigate the safety and efficacy of IFA in
reducing AL rate following elective rectal cancer sur-
gery. Two mechanistic sub-studies will explore the role
of the rectal microbiome in AL and the value of preop-
erative CT angiography and perfusion CT in predicting
AL. The primary outcome measure will be clinical AL
within 90 days of surgery. Secondary outcome measures
will include all AL (clinical and radiological), complica-
tions and re-interventions, change to anastomosis con-
struction, use of stoma, as well as cost effectiveness and
QoL outcomes.
Trial sites and participating surgeons
IntAct will recruit from ≥ 25 European sites (Table 1).
Participating sites must have access to an NIR laparo-
scopic or robotic system and be able to recruit a mini-
mum of 12 patients per year. Surgeons must have
experience of using IFA in three previous laparoscopic
or robotic-assisted ARs.
Trial population
Patients will be over 18 years of age with a diagnosis of
adenocarcinoma of the rectum (defined as a lower
margin ≤ 15 cm from the anal verge on endoscopic or
radiological assessment) that is suitable for elective
curative resection by high or low anterior resection.
The procedure can be performed either laparoscopically
or with robotic assistance.
Patients will be ineligible if not undergoing primary
colorectal/anal anastomosis or if undergoing syn-
chronous colonic resection. Patients with recurrent or
locally advanced rectal cancer requiring extended or
multivisceral excision will be excluded. Other exclusion
criteria include: coexistent colorectal pathology (e.g.
inflammatory bowel disease); previous remote pelvic
radiotherapy (e.g. previous prostate cancer treated with
radiotherapy); antibiotic medication within 8 weeks of
randomization; pregnancy; allergy to iodine or ICG;
and hepatic or renal dysfunction.
Trial design
IntAct is a prospective, unblinded, parallel-group, multi-
centre, European, randomized controlled trial compar-
ing surgery with IFA against standard care (surgery with
no IFA). The primary outcome is the difference in clini-
cal AL rate at 90 days postsurgery between the two
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groups. The Clinical Trials Research Unit (CTRU) at
the University of Leeds will co-ordinate the trial. The
trial will run for 3 years and all patients will be fol-
lowed-up for 90 days from the date of surgery. UK
patients recruited within the first 2 years of enrolment
will provide QoL and health resource utilization data at
1 year (Fig. 1).
Sample size
A total of 880 patients will be recruited over 36 months
and randomized on a 1:1 basis to receive surgery, either
with or without IFA. A computer-generated minimiza-
tion program incorporating a random element will be
used to ensure that treatment groups are well balanced
(Fig. 1).
A formal interim analysis will be conducted once pri-
mary end-point data are available for 554 patients. In the
UK, the first 200 patients recruited will take part in the
microbiome sub-study, and 75 patients randomized to
IFA will take part in the optional perfusion sub-study.
Randomization timing
Randomization will be performed at the time of obtain-
ing informed consent. This will be as close to date of
surgery as is feasibly possible and no more than 28 days
prior to surgery.
Table 1 IntAct anticipated participating sites.
Principal investigator Hospital City Country
Europe
Professor Luigi Boni Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico
Milan Italy
Professor Frederic Ris Geneva University Hospitals Geneva Switzerland
Professor Ronan Cahill Mater Misericordiae University Hospital,
Dublin & Mater Private Hospital
Dublin Ireland
Prof. Dr. med. Christoph Reißfelder Chirurgische Klinik Universit€atsmedizin Mannheim Germany
PD Dr. med. Christoph Holmer Charite – Universit€atsmedizin Berlin Berlin Germany
Professor Albert Wolthuis University Hospital Leuven Leuven Belgium
Mr Roel Hompes AMC Amsterdam Amsterdam The Netherlands
Dr Gabriele Barabino CHU Sainte Etienne Saint Etienne France
Professor Pierre-Emmanuel Colombo ICM Val d’Aurelle Montpellier Montpellier France
Professor Giovanni Dapri Saint-Pierre University Hospital Brussels Belgium
UK
Professor David Jayne St James’ University Hospital Leeds
Mr Chris Cunningham Churchill Hospital Oxford
Ms Deborah Nicol Worcestershire Royal Hospital Worcester
Mr Mark Coleman Derriford Hospital NHS Trust Plymouth
Mr Manish Chand University College Hospital (UCLH) London
Mr James Horwood University Hospital of Wales Cardiff
Mr Peter Coyne Royal Victoria Infirmary Newcastle
Mr Mohamed Adhnan Thaha The Royal London Hospital London
Professor Tim Rockall The Royal Surrey County Hospital Surrey
Mr Charles Evans University Hospital Coventry Coventry
Mr Athur Harikrishnan Northern General Hospital Sheffield
Mr John Griffith Bradford Royal Infirmary Bradford
Mr Ioannis Peristerakis Royal Preston Hospital Preston
Mr Henry Tilney Frimley Park Hospital Surrey
Mr Danilo Miskovic St Mark’s Hospital London
Mr Paul Mackey Musgrove Park Hospital Taunton
Mr Stephen Dalton Royal United Hospital Bath Bath
Mr Praminthra Chitsabesan York Teaching Hospital York
Information correct at time of publication. Participating site and/or the designated principal investigator may change throughout
the course of the trial.
At least 25 sites across the UK and Europe will participate in IntAct. Site are expected to recruit a minimum of 12 patients per year.
Additional sites will be added in due course.
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IntAct Trial Schema
Microbiome sub-study
3–5 days post op: Faecal samples (mucosal & lumen)
30 days post-operation FU: Clinical assessment, QoL completion (QLQ-C30, QLQ-CR29, EQ-
5D & LARS score), health resource use
90 days post-operation FU: Clinical assessment, QoL completion (QLQ-C30, QLQ-CR29, EQ-
12 months post-operation FU*: Re-interventions, QoL completion (QLQ-C30, QLQ-CR29,
EQ-5D). UK only. *if this time point falls within the planned follow-up period.
5D & LARS score), health resource use
4–6 weeks post-operation: rectal contrast enema 
Microbiome sub-study
Intra-op: Faecal samples (mucosal & lumen)
Microbiome sub-study 
Intra-op: Faecal samples (mucosal & lumen)
PERFUSION SUB-STUDY CONSENT-
OPTIONAL (Select sites)
ANTERIOR RESECTION OPERATION (NO IFA)
Surgery with IFA arm
n = 440
Surgery with no IFA 
standard care arm
n = 440
Microbiome sub-study 
Pre-op: Faecal samples (mucosal & lumen)
MAIN TRIAL CONSENT
RANDOMIZATION (1:1)
Minimisation incorporating a random element, stratified by treating surgeon, gender, ASA, radiological T-stage, neoadjuvant 
therapy and tumour position.
Baseline data collection:Demographics, standard investigations (radiological, TNM stage, CRM involvement), tumour 
characteristics, pre-op treatment, blood parameters. QoL completion (QLQ-C30, QLQ-CR29, EQ-5D & LARS score).
Microbiome sub-study 
Pre-op: Faecal samples (mucosal & lumen)
Perfusion sub-study
Pre-op: CTP and CTA scan 
ANTERIOR RESECTION OPERATION USING IFA
Setting: 25 centres throughout Europe.  
Population: Patients with a diagnosis of rectal cancer suitable for elective laparoscopic or robotic anterior resection with 
anastomosis 
Inclusion criteria: Adult patients aged 18 years or older, diagnosis of rectal cancer (defined as a lower margin ≤15 cm from the 
anal verge on endoscopic or radiological examination), suitable for curative high or low anterior resection, suitable for elective 
laparoscopic or robotic anterior resection with anastomosis, ASA ≤3. Exclusion criteria: Patients not undergoing colo-
rectal/anal anastomosis, patients undergoing synchronous colonic resections, locally advanced rectal cancer requiring extended 
or multi-visceral excision, coexistent colorectal pathology (e.g. inflammatory bowel disease); previous remote pelvic 
radiotherapy (e.g.  previous prostate cancer treated with radiotherapy); antibiotic medication within 8 weeks of randomization; 
pregnancy; allergy to iodine or ICG; and hepatic or renal dysfunction.
Figure 1 IntAct trial Schema. ASA, American Society of Anesthesiologists; CRM, circumferential resection margin; CTA, CT
angiography; CTp, perfusion CT; FU, follow-up; ICG, indocyanine green; IFA, intra-operative fluorescence angiography; Intra-op,
intra-operative; LARS, low anterior resection syndrome; QoL, quality of life; Pre-op, preoperative; post op, postoperative.
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Interventions
Standard care arm (no IFA)
Laparoscopic or robot-assisted AR (high or low) will be
performed as per surgeon preference. Perfusion assess-
ment will be performed with white light (WL) only.
IFA arm
For participants randomized to surgery with IFA, AR (AR)
will be performed according to the surgeon’s usual tech-
nique, using either a laparoscopic or a robotic approach.
Two IFA assessments are required, each involving an
intravenous bolus of 0.1 mg/kg of ICG. The first
assessment will be performed after rectal mobilization
but before bowel resection. Under WL laparoscopy, the
point of planned bowel transection will be marked.
Using either an intra- or extracorporeal IFA technique,
the time to first fluorescence and any change in the
planned bowel transection point following IFA will be
recorded. The fluorescence intensity will be graded
using a semi-quantifiable scale. The second assessment
will be performed after construction of the anastomosis.
This can be either an intracorporeal or endoluminal
assessment following ICG administration, with time to
fluorescence and fluorescence intensity recorded. One
additional IFA assessment is permitted at the operating
surgeon’s discretion.
Sub-study interventions
The first 200 UK patients recruited to either intervention
group will provide rectal luminal and mucosal faecal sam-
ples at baseline, intra-operatively and 3–5 days post-
surgery. Rectal bacteria will be classified into taxonomic
groups by 16S ribosomal RNA (rRNA) gene analysis and
assessed for collagenase activity on solid agar.
At selected UK centres, the first 75 patients recruited
to the IFA intervention can participate in the optional
contrast-enhanced CT angiography and perfusion CT
sub-study. The perfusion CT scan will be centred on
the planned site of rectal anastomosis and performed
within 14 days of planned surgery. This will allow the
attenuation over time to be plotted for the rectal wall
and for regional blood flow, blood volume and perme-
ability surface area product to be derived. Perfusion CT
will be immediately followed by the CT angiography
scan to allow anatomical evaluation of the vasculature
with image reconstructions in the sagittal and coronal
planes and three-dimensional (3D) volume rendering.
Postoperative care
Postoperative care will be as per institutional protocol.
All participants will receive clinical assessment at 30 and
90 days postsurgery and will undergo a rectal contrast
enema around 4–6 weeks postsurgery to detect radio-
logical evidence of AL (unless AL has been confirmed
by alternative means).
Patient completed questionnaires
Patient completed questionnaires measuring QoL (EQ-
5D, EORTC QLQ-C30, EORTC QLQ-CR29 and
LARS), and Health Resource Use questionnaires, will
be completed at baseline, and 30 and 90 days post-
surgery. There will be an additional QoL questionnaire
pack (EQ-5D, EORTC QLQ-C30, EORTC QLQ-
CR29) posted to UK patients at 1 year postsurgery if
this time point falls before the end of the planned fol-
low-up period (i.e. 90 days following the last patient’s
operation) (Table 2).
Data collection and management
Participating sites will record patient data on trial-speci-
fic case report forms (CRFs). Data will be collected at
baseline, intra-operatively and at clinical assessment on
days 30 and 90 postsurgery. Hospital readmission
details from medical notes will be collected for UK
patients only at 1 year postsurgery, if this time point
falls before the end of the planned follow-up period.
Participant completed data will be collected as per
Table 2. The CTRU will provide overall data and trial
management.
Outcomes
The primary end-point of the main trial is clinical AL
rate within 90 days of surgery. AL is defined, according
to the International Study Group definition [34], as a
confirmed defect of the intestinal wall at the anasto-
motic site (including suture and staple lines of neorectal
reservoirs) leading to a communication between the
intra- and extraluminal compartments that has an
impact on patient management. An abscess or collection
of fluid in close proximity to the anastomosis will be
deemed as an AL. This equates to Grades B and C in
the International Study Group definition.
The secondary end-points are AL (all grades), change
in intra-operative decision-making (including change to
planned anastomosis), use of stoma, complications and
re-interventions, QoL outcomes measures, low anterior
resection syndrome (LARS) scores and health resource
utilization measures.
The CT perfusion sub-study will examine the effects
of radiotherapy and anatomical variance in vascular anat-
omy on rectal blood flow and their relationship to AL.
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It will also provide additional data to aid interpretation
of results in cases where poor IFA perfusion is observed.
The microbiome sub-study will provide data on the tax-
onomic classification and collagenase activity of rectal
microorganisms, the effect on mechanical bowel prepa-
ration and surgery on the microbiome and will allow
correlation with the rate of AL in the study population.
Quality of life
Trial participants will complete several questionnaires to
capture health status (EQ-5D-5L) and QoL (QLQ-C30
and QLQ-CR29) at 30 and 90 days postsurgery (and at
day 365 where permitted). Patients without a defunc-
tioning stoma will provide information on bowel func-
tion and LARS.
Health economic assessment
Analyses will report the differences in the cost of health
and social care service utilization between groups and the
incremental cost-effectiveness ratios using both the same
primary outcome as the trial and quality adjusted life
years. Resource use will be collected through investigator
and participant completed forms at the 30- and 90-day
postsurgery assessment. Unit costs for resources will be
obtained from national sources, such as the NHS Refer-
ence cost database. The nonparametric bootstrap method
will be used to produce a within-trial probabilistic sensi-
tivity analysis of the incremental cost-effectiveness ratio.
IntAct will present the expected incremental cost-effec-
tiveness ratio, the scatterplot on the cost-effectiveness
plane, the 95% cost-effectiveness ellipse and the cost-
effectiveness acceptability curve [35].
Statistical methods
A sample size of 880 patients is required to show a
reduction in clinical AL rate from 12.0% to 6.0% at a
two-sided 5% level of significance with 80% power,
allowing for a formal interim analysis (details below)
and a 10% drop-out rate.
The rate of clinical AL in each trial arm will be
summarized according to trial arm alongside measures
of uncertainty. The primary analysis will compare AL
rates between the arms using multilevel logistic
Table 2 Schedule of events.
Event
Baseline/
Pre-op Surgery
3–5 days
postop
30 days
postop
4–6 weeks
postop
90 days
postop
1 year
postop
(UK only)
Clinical
assessments/
investigations
Clinical examination U U U
Pre-operative bloods U
Operative details U
Complications U U U
Trial consent U
Microbiome sub-study
(faecal samples)
U U U
Perfusion sub-study
(CTP and CTA) – OPTIONAL
U
Rectal contrast enema scan U
Data collection
time points
Eligibility CRF U
Baseline CRF U
Operative CRF U
30 days postsurgery f/up CRF U
90 days postsurgery f/up CRF U
1 year postsurgery f/up CRF U*
Participant
completed
questionnaires
EQ-5D-5L U U U U*
EORTC QLQ-C30 and
QLQ-CR29
U U U U*
LARS U U U
Resource use (UK sites only) U U U
CRF, case report form; CTA, CT angiography; CTp, perfusion CT; f/up, follow-up; LARS, low anterior resection syndrome;
postop, postoperative; Pre-op, preoperative.
*Only required if this time point falls before the end of the planned follow-up period (i.e. 90 days following the last participant’s
operation).
ª 2018 The Authors. Colorectal Disease published by John Wiley & Sons Ltd
on behalf of Association of Coloproctology of Great Britain and Ireland.6
Intra-operative fluorescence angiography to prevent anastomotic leak G. Armstrong et al.
regression incorporating random effects with respect
to surgeon and adjusting for the stratification factors.
This approach will be used to test the two-sided
hypothesis that the AL rate is equal in both arms (i.e.
OR = 1), considering the 95% CI and the P-value
yielded by a Wald test of the treatment allocation
regression coefficient.
The formal interim analysis will be conducted on
unblinded data once primary end-point data are available
for 554 participants. At the interim analysis, a value of
P < 0.0146 will be considered to be sufficiently strong evi-
dence of efficacy for early stopping. At the final primary
analysis, a value of P < 0.0456 will be considered as ‘sig-
nificant’ in order to maintain the overall type I error rate
(as per O’Brien and Fleming) [36]. The timing of the
interim analysis was chosen such that it occurs as soon as
possible after the sub-studies have been completed, whilst
maintaining acceptable operating characteristics.
Safety evaluation and reporting of adverse events
For the purpose of this surgical trial, adverse events will
be termed as complications. A complication is defined
as an untoward medical event in a participant which has
a causal relationship to the trial. The trial includes the
surgical intervention and any trial-specific interventions.
Information on all complications will be collected, this
includes information volunteered by the participant or
discovered by the investigator.
Trial organization, administration and governance
IntAct is funded by the Efficacy and Mechanism Evalua-
tion (EME) Programme, an MRC and NIHR partner-
ship (Grant Reference: 14/150/62). The trial sponsor
is the University of Leeds. IntAct will be overseen by an
independent Data Monitoring and Ethics Committee
(DMEC) and Trial Steering Committee. The study has
been designed with input from public and patient
groups and is supported by Bowel Cancer UK.
Ethical considerations
The trial will be conducted in accordance with the prin-
ciples of Good Clinical Practice (GCP) in clinical trials,
the NHS Research Governance Framework and through
adherence to CTRU Standard Operating Procedures
(SOPs). The trial will operate using the recommenda-
tions guiding physicians in biomedical research involv-
ing human subjects adopted by the 18th World Medical
Assembly, Helsinki, Finland, 1964, amended at the
64th World Medical Association General Assembly, For-
taleza, Brazil, October 2013 [37].
IntAct has been granted ethical approval by the UK
Health Research Authority (HRA) Research Ethics
Committee (REC).
Discussion
There has been no advance in eliminating the most
feared complication of gastrointestinal surgery – AL – in
the past 50 years. This proposal evaluates a new tech-
nology – IFA – which, for the first time, allows sur-
geons to assess intra-operative anastomotic perfusion
easily, could help to reduce the incidence of AL signifi-
cantly. The incorporation of two sub-studies evaluating
rectal blood supply and perfusion in patients with and
without neoadjuvant chemo/radiotherapy, and the role
of the rectal microbiome in AL, adds exciting dimen-
sions that will further inform our understanding of the
mechanisms underlying AL.
Although previous studies have suggested that IFA
can reduce the risk of AL, the scientific rigour of these
evaluations was limited. PILLAR II was a non-rando-
mized, observational study including a mixed cohort of
patients with malignant and benign colorectal condi-
tions and restricted to the USA. No assessment was
made of QoL or cost-effectiveness, and its generalizabil-
ity is questionable. Other studies have consisted mainly
of small observational series and are subject to selection
and reporting biases [13,15–17,19,33].
As yet, no randomized controlled trial of IFA as a
method of reducing AL in rectal cancer surgery has
been reported. The PILLAR III study (ClinicalTrials.gov
registry identifier NCT02205307) was a multicentre
randomized controlled trial of IFA in the USA and has
terminated early. PILLAR III recruited 330 of a planned
550–900 patients undergoing AR (≥ 10 cm from the
anal verge) before May 2017 [38]. This industry-funded
trial used clinical AL as the primary end-point and aimed
to assess the efficacy of IFA in preventing AL. IntAct dif-
fers in design to PILLAR III in assessing both clinical
and radiological AL and with the inclusion of cost-
effectiveness as trial end-points. It investigates a
European surgical population where practice can differ
from that in the USA. Importantly, IntAct includes two
exciting sub-studies that may help in understanding the
mechansims underlying AL.
If IntAct confirms the efficacy of IFA in minimizing
AL it will have widespread implications, not just for rectal
cancer surgery but potentially for any surgery involving
an anastomosis. AL is a burden on valuable healthcare
resources; the average cost of AL following AR is
£17 220 [39]. It is one of the leading causes of death fol-
lowing rectal cancer surgery, with around 20–30% of all
30-day mortality being directly attributed to AL [7,8]. In
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those patients who survive AL, it is a cause of long-term
morbidity, associated with poor bowel function, reduced
QoL, increased risk of cancer recurrence and high rates of
permanent stoma [5,6,9,40].
If IntAct confirms the hypothesis that IFA reduces
the rate of AL, it will inform the uptake and provision
of the technology, with potential cost savings for
healthcare providers and safer surgery for patients.
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